Amineptine

Identification

Name
Amineptine
Accession Number
DB04836
Type
Small Molecule
Groups
Illicit, Withdrawn
Description

The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Amineptine hydrochlorideNot AvailableNot AvailableVDPUXONTAVMIKZ-UHFFFAOYSA-N
International/Other Brands
Directim / Maneon / Neolior / Provector / Survector (Servier) / Viaspera
Categories
UNII
A5P604A12R
CAS number
57574-09-1
Weight
Average: 373.916
Monoisotopic: 373.180856852
Chemical Formula
C22H28ClNO2
InChI Key
VDPUXONTAVMIKZ-UHFFFAOYSA-N
InChI
InChI=1S/C22H27NO2.ClH/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22;/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25);1H
IUPAC Name
N-(6-carboxyhexyl)tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-aminium chloride
SMILES
[Cl-].OC(=O)CCCCCC[NH2+]C1C2=CC=CC=C2CCC2=CC=CC=C12

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Not Available
Pharmacodynamics

Amineptine is an atypical tricyclic antidepressant.

Mechanism of action

Amineptine selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, thus exerting a powerful and fast-acting antidepressant effect.

TargetActionsOrganism
USodium-dependent noradrenaline transporterNot AvailableHuman
USodium-dependent serotonin transporterNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

48 minutes for the parent drug and 2.5 hours for the metabolites.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Amineptine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineAmineptine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Amineptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineAmineptine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Amineptine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineAmineptine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineAmineptine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Amineptine.Experimental
AcenocoumarolAmineptine may increase the anticoagulant activities of Acenocoumarol.Approved
AgmatineAmineptine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AlogliptinThe serum concentration of Amineptine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Amineptine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AltretamineAltretamine may increase the orthostatic hypotensive activities of Amineptine.Approved
AmobarbitalThe metabolism of Amineptine can be increased when combined with Amobarbital.Approved, Illicit
AmphetamineAmineptine may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Amineptine can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Amineptine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Amineptine can be increased when it is combined with Apixaban.Approved
ApomorphineAmineptine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineAmineptine may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Amineptine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Amineptine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Amineptine can be increased when it is combined with Argatroban.Approved, Investigational
AsunaprevirThe serum concentration of Amineptine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Amineptine can be increased when it is combined with Atazanavir.Approved, Investigational
BambuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Amineptine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Amineptine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Amineptine can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Amineptine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Amineptine.Withdrawn
BenzamidineThe serum concentration of Amineptine can be increased when it is combined with Benzamidine.Experimental
BenzphetamineAmineptine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
BethanidineAmineptine may decrease the antihypertensive activities of Bethanidine.Approved
BivalirudinThe serum concentration of Amineptine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Amineptine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BrimonidineAmineptine may decrease the antihypertensive activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Amineptine.Experimental
BromocriptineAmineptine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BupropionThe metabolism of Amineptine can be decreased when combined with Bupropion.Approved
CamostatThe serum concentration of Amineptine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Amineptine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Amineptine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Amineptine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Amineptine can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the serotonergic activities of Amineptine.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Amineptine is combined with Celiprolol.Approved, Investigational
ChlorphentermineAmineptine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
CholesterolThe serum concentration of Amineptine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Amineptine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Amineptine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Amineptine can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Amineptine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Amineptine can be increased when it is combined with Cinacalcet.Approved
CirazolineAmineptine may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Amineptine is combined with Citalopram.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClonidineAmineptine may decrease the antihypertensive activities of Clonidine.Approved
ClorindioneAmineptine may increase the anticoagulant activities of Clorindione.Experimental
Dabigatran etexilateThe serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate.Approved
DarexabanThe serum concentration of Amineptine can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Amineptine can be increased when it is combined with Darunavir.Approved
DelanzomibThe serum concentration of Amineptine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Amineptine can be increased when it is combined with Delapril.Experimental
DesmopressinThe risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.Approved
DexmedetomidineAmineptine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amineptine.Approved
DextroamphetamineAmineptine may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DicoumarolAmineptine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionAmineptine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydroergotamineAmineptine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DiphenadioneAmineptine may increase the anticoagulant activities of Diphenadione.Experimental
DipivefrinAmineptine may decrease the antihypertensive activities of Dipivefrin.Approved
DobutamineThe risk or severity of adverse effects can be increased when Amineptine is combined with Dobutamine.Approved
DroxidopaAmineptine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Amineptine.Approved
EcabetThe serum concentration of Amineptine can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Amineptine can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Amineptine can be increased when it is combined with Elafin.Investigational
EnalaprilThe serum concentration of Amineptine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Amineptine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Amineptine can be increased when it is combined with Enalkiren.Experimental
EphedraAmineptine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Amineptine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineAmineptine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgotamineAmineptine may decrease the antihypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Amineptine is combined with Escitalopram.Approved, Investigational
Ethyl biscoumacetateAmineptine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtomidateAmineptine may decrease the antihypertensive activities of Etomidate.Approved
FaldaprevirThe serum concentration of Amineptine can be increased when it is combined with Faldaprevir.Investigational
FenoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Fenoterol.Approved, Investigational
FluindioneAmineptine may increase the anticoagulant activities of Fluindione.Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amineptine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amineptine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Amineptine can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Amineptine can be increased when it is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the serotonergic activities of Amineptine.Approved, Investigational, Vet Approved
GabexateThe serum concentration of Amineptine can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Amineptine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GepefrineAmineptine may increase the stimulatory activities of Gepefrine.Experimental
GM6001The serum concentration of Amineptine can be increased when it is combined with GM6001.Experimental
GuanabenzAmineptine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineAmineptine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HarmalineHarmaline may increase the serotonergic activities of Amineptine.Experimental
HexobarbitalThe metabolism of Amineptine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Amineptine.Experimental
HydroxyamphetamineAmineptine may increase the stimulatory activities of Hydroxyamphetamine.Approved
IdraparinuxThe serum concentration of Amineptine can be increased when it is combined with Idraparinux.Investigational
ImidaprilThe serum concentration of Amineptine can be increased when it is combined with Imidapril.Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Indacaterol.Approved
IndinavirThe serum concentration of Amineptine can be increased when it is combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Amineptine.Approved, Investigational
Iofetamine I-123Amineptine may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the serotonergic activities of Amineptine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Amineptine.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Amineptine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Amineptine is combined with Isoetarine.Approved
IsoflurophateThe serum concentration of Amineptine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoprenalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Isoprenaline.Approved
IxazomibThe serum concentration of Amineptine can be increased when it is combined with Ixazomib.Approved
LepirudinThe serum concentration of Amineptine can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Amineptine can be increased when it is combined with Letaxaban.Investigational
LevonordefrinAmineptine may decrease the antihypertensive activities of Levonordefrin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Amineptine is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Amineptine.Approved
LinagliptinThe serum concentration of Amineptine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Amineptine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Amineptine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Amineptine.Approved
LisdexamfetamineAmineptine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Amineptine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Amineptine.Approved
LofexidineAmineptine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Amineptine can be increased when it is combined with Lopinavir.Approved
MebanazineMebanazine may increase the serotonergic activities of Amineptine.Withdrawn
MelagatranThe serum concentration of Amineptine can be increased when it is combined with Melagatran.Experimental
MephedroneAmineptine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineAmineptine may increase the vasopressor activities of Mephentermine.Approved
MetaraminolAmineptine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MethamphetamineAmineptine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Amineptine can be increased when combined with Methohexital.Approved
MethoxamineAmineptine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyphenamineAmineptine may increase the stimulatory activities of Methoxyphenamine.Experimental
Methylene blueAmineptine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.Approved, Investigational
MethylphenobarbitalThe metabolism of Amineptine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amineptine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amineptine.Approved
MidodrineAmineptine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineAmineptine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MinaprineMinaprine may increase the serotonergic activities of Amineptine.Approved
MMDAAmineptine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Amineptine.Approved
MoexiprilThe serum concentration of Amineptine can be increased when it is combined with Moexipril.Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Amineptine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Amineptine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Amineptine can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineAmineptine may decrease the antihypertensive activities of Naphazoline.Approved
NelfinavirThe serum concentration of Amineptine can be increased when it is combined with Nelfinavir.Approved
NialamideNialamide may increase the serotonergic activities of Amineptine.Withdrawn
NicorandilAmineptine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NitroaspirinThe serum concentration of Amineptine can be increased when it is combined with Nitroaspirin.Investigational
NorepinephrineAmineptine may decrease the antihypertensive activities of Norepinephrine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Amineptine.Withdrawn
OlodaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Amineptine can be increased when it is combined with Omapatrilat.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Orciprenaline.Approved
OtamixabanThe serum concentration of Amineptine can be increased when it is combined with Otamixaban.Investigational
OxymetazolineAmineptine may decrease the antihypertensive activities of Oxymetazoline.Approved
PaliperidoneAmineptine may decrease the antihypertensive activities of Paliperidone.Approved
PargylinePargyline may increase the serotonergic activities of Amineptine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amineptine.Approved, Investigational
PentobarbitalThe metabolism of Amineptine can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideAmineptine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Amineptine can be increased when it is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Amineptine.Approved
PhenindioneAmineptine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Amineptine.Withdrawn
PhenobarbitalThe metabolism of Amineptine can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Amineptine.Withdrawn
PhenprocoumonAmineptine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineAmineptine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineAmineptine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Amineptine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhosphoramidonThe serum concentration of Amineptine can be increased when it is combined with Phosphoramidon.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Pirbuterol.Approved
PirlindolePirlindole may increase the serotonergic activities of Amineptine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Amineptine.Withdrawn
PrimidoneThe metabolism of Amineptine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Amineptine can be increased when it is combined with Prinomastat.Investigational
ProcarbazineProcarbazine may increase the serotonergic activities of Amineptine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Procaterol.Approved, Investigational
PseudoephedrineAmineptine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuinaprilThe serum concentration of Amineptine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineAmineptine may increase the QTc-prolonging activities of Quinidine.Approved
RacecadotrilThe serum concentration of Amineptine can be increased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Amineptine can be increased when it is combined with Ramipril.Approved
RasagilineRasagiline may increase the serotonergic activities of Amineptine.Approved
RemikirenThe serum concentration of Amineptine can be increased when it is combined with Remikiren.Approved
RisperidoneAmineptine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronAmineptine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Amineptine is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Amineptine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Amineptine can be increased when it is combined with Rivaroxaban.Approved
RopiniroleAmineptine may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
S-3304The serum concentration of Amineptine can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Amineptine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Amineptine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Amineptine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Amineptine can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Amineptine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Amineptine.Approved, Investigational, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amineptine.Approved
SimeprevirThe serum concentration of Amineptine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Amineptine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Amineptine can be increased when it is combined with Sivelestat.Investigational
Sodium phosphateThe risk or severity of adverse effects can be increased when Amineptine is combined with Sodium phosphate.Approved
SpiraprilThe serum concentration of Amineptine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Amineptine can be increased when combined with St. John's Wort.Investigational, Nutraceutical
TelaprevirThe serum concentration of Amineptine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TemocaprilThe serum concentration of Amineptine can be increased when it is combined with Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Amineptine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Amineptine is combined with Terbutaline.Approved
ThiamylalThe metabolism of Amineptine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Amineptine can be increased when combined with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Amineptine can be increased when it is combined with Thiorphan.Experimental
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Amineptine.Approved
TioclomarolAmineptine may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Amineptine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineAmineptine may decrease the antihypertensive activities of Tizanidine.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Amineptine.Approved
TramadolAmineptine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Amineptine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amineptine.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Amineptine.Approved
UbenimexThe serum concentration of Amineptine can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Amineptine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Amineptine can be increased when it is combined with Valproic Acid.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amineptine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Amineptine is combined with Vilanterol.Approved
VildagliptinThe serum concentration of Amineptine can be increased when it is combined with Vildagliptin.Approved, Investigational
WarfarinAmineptine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Amineptine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineAmineptine may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Amineptine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Amineptine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZofenoprilThe serum concentration of Amineptine can be increased when it is combined with Zofenopril.Experimental
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.

References

Synthesis Reference

Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale. Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale.

US3758528
General References
  1. Vaugeois JM, Corera AT, Deslandes A, Costentin J: Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor. Pharmacol Biochem Behav. 1999 Jun;63(2):285-90. [PubMed:10371658]
  2. Grupper C: [New iatrogenic acne: acne caused by amineptin (Survector)]. Ann Dermatol Venereol. 1988;115(11):1174-6. [PubMed:2977079]
  3. Thioly-Bensoussan D, Charpentier A, Triller R, Thioly F, Blanchet P, Tricoire N, Noury JY, Grupper C: [Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases]. Ann Dermatol Venereol. 1988;115(11):1177-80. [PubMed:2977080]
  4. Vexiau P, Gourmel B, Husson C, Castot A, Rybojad M, Julien R, Fiet J, Puissant A, Cathelineau G: [Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases]. Ann Dermatol Venereol. 1988;115(11):1180-2. [PubMed:2977081]
  5. Teillac D, Weber MJ, Lowenstein W, de Prost Y: [Acne caused by Survector]. Ann Dermatol Venereol. 1988;115(11):1183-4. [PubMed:2977082]
External Links
PubChem Compound
34869
PubChem Substance
46509012
ChemSpider
32090
ChEBI
50003
ChEMBL
CHEMBL1697712
Therapeutic Targets Database
DCL000340
Wikipedia
Amineptine
ATC Codes
N06AA19 — Amineptine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226-230Melen,C., Danree, B.and Poignant, J.C.; US.Patent 3,758,528; September 11,1973; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale Melen, C., Danree, B. and Poignant, J.C.; U.S. Patent 3,821,249; June 28, 1974; assigned to Societe en nom Collectif Science Union et Cie; Societe Francaise de Recherche Medicale
Predicted Properties
PropertyValueSource
Water Solubility1.84e-05 mg/mLALOGPS
logP0.99ALOGPS
logP2.74ChemAxon
logS-7.3ALOGPS
pKa (Strongest Acidic)4.41ChemAxon
pKa (Strongest Basic)9.46ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area53.91 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity112.63 m3·mol-1ChemAxon
Polarizability39.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.927
Blood Brain Barrier+0.9384
Caco-2 permeable-0.5548
P-glycoprotein substrateNon-substrate0.5457
P-glycoprotein inhibitor INon-inhibitor0.9324
P-glycoprotein inhibitor IINon-inhibitor0.8538
Renal organic cation transporterNon-inhibitor0.6998
CYP450 2C9 substrateNon-substrate0.7559
CYP450 2D6 substrateNon-substrate0.7653
CYP450 3A4 substrateNon-substrate0.5897
CYP450 1A2 substrateNon-inhibitor0.5434
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.7593
CYP450 2C19 inhibitorNon-inhibitor0.8446
CYP450 3A4 inhibitorNon-inhibitor0.7073
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9165
Ames testAMES toxic0.6805
CarcinogenicityNon-carcinogens0.8651
BiodegradationNot ready biodegradable0.7096
Rat acute toxicity2.9526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9341
hERG inhibition (predictor II)Inhibitor0.6018
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Medium-chain fatty acids / Aralkylamines / Amino acids / Monocarboxylic acids and derivatives / Dialkylamines / Carboxylic acids / Organopnictogen compounds / Organic oxides / Hydrochlorides / Hydrocarbon derivatives
show 1 more
Substituents
Dibenzocycloheptene / Medium-chain fatty acid / Aralkylamine / Fatty acid / Fatty acyl / Amino acid or derivatives / Amino acid / Carboxylic acid derivative / Carboxylic acid / Secondary aliphatic amine
show 13 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
hydrochloride (CHEBI:50003)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on September 12, 2007 03:05 / Updated on December 01, 2017 17:16